CN106511996B - Emulsion type adjuvant and preparation method thereof for aftosa vaccine - Google Patents
Emulsion type adjuvant and preparation method thereof for aftosa vaccine Download PDFInfo
- Publication number
- CN106511996B CN106511996B CN201610963355.XA CN201610963355A CN106511996B CN 106511996 B CN106511996 B CN 106511996B CN 201610963355 A CN201610963355 A CN 201610963355A CN 106511996 B CN106511996 B CN 106511996B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- parts
- emulsion type
- adjuvant
- aftosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The present invention is provided to emulsion type adjuvants of aftosa vaccine and preparation method thereof, are related to field of pharmaceutical preparations.It for the emulsion type adjuvant of aftosa vaccine, is grouped as by the group of following mass parts: 50-65 parts of mineral oil, 10-35 parts of vitamin E, 3-5 parts of castor oil ethyl oxide, 2-8 parts of Tween 80,2-6 parts of n-amyl alcohol, 1-4 parts and deionized water 1-5 parts of Brij-721.The present invention also provides the aftosa vaccines and preparation method thereof containing emulsion type adjuvant.Aftosa vaccine containing the adjuvant under the premise of stability, immunoenhancement result are preferable, in the short period can completely passive object absorb, avoid inoculation position inflammation, therefore significantly reduce side reaction.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, and in particular to for the emulsion type adjuvant of aftosa vaccine and its preparation side
Method.
Background technique
The medium oil adjuvant of animal vaccine is most widely used, and immunoenhancement result is best.Containing there are three types of oil-adjuvant vaccines
Dosage form: Water-In-Oil (W/O) type, W/O/W (W/O/W) type and oil-in-water (O/W) type.
Currently, containing, oil-adjuvant vaccine is the most universal with W/O (oil emu), enhancing immune effect is best, cannot but exist
The disadvantages of mineral oil content of metabolism is high, large viscosity and toxicity are strong.The animals such as pig, dog, cat are especially quick to the dose vaccine
Sense, which has limited the application of W/O dosage form in practice.And O/W dosage form the shortcomings that overcoming W/O, but adjuvanticity is too weak, improves
The ability of immune effect is limited, is not able to satisfy the demand of aquaculture.
Common adjuvant is W/O/W (W/O/W) type emulsion in W/O/W (W/O/W) type vaccine.The prior art
In, W/O/W (W/O/W) type emulsion includes206 adjuvant of ISA (French SEPPIC company) and contain
The adjuvant of a large amount of mineral oil, although the vaccine immunocompetence containing these adjuvants is high, the long period can be by after being immunized
Animal fully absorbs, the easy inflammation of inoculation position, therefore side reaction is larger.
Summary of the invention
The object of the present invention is to provide the emulsion type adjuvant for aftosa vaccine, the aftosa vaccine containing the adjuvant exists
Under the premise of stability, immunoenhancement result are preferable, in the short period can completely passive object absorb, avoid inoculation position from sending out
Inflammation, therefore significantly reduce side reaction.
It is a further object of the present invention to provide the aftosa vaccine containing emulsion type adjuvant, the vaccine stability, immune effect
Fruit is preferable, within a short period of time can completely passive object absorb, avoid inoculation position inflammation, therefore significantly reduce secondary anti-
It answers.
Another object of the present invention is to provide the preparation method of above-mentioned vaccine, and this method is simple, efficiently, safety.
The purpose of the present invention adopts the following technical scheme that realization:
For the emulsion type adjuvant of aftosa vaccine, it is grouped as by the group of following mass parts:
50-65 parts of mineral oil,
10-35 parts of vitamin E,
3-5 parts of castor oil ethyl oxide,
2-8 parts of Tween 80,
2-6 parts of n-amyl alcohol,
1-4 parts of Brij-721,
1-5 parts of deionized water.
In the present invention, the castor oil ethyl oxide is Emulsogen EL360, the Brij-721
For stearyl alcohol polyoxyethylene (21) ether.
The present invention also provides the preparation methods of the emulsion type adjuvant for aftosa vaccine, and each component is mixed, is stirred
Mix uniformly sterilizing.
The present invention also provides the aftosa vaccines for containing the emulsion type adjuvant.
In the present invention, the vaccine is made of the emulsion type adjuvant and foot-and-mouth disease antigen.
In preferred technical solution, the mass ratio of the emulsion type adjuvant and foot-and-mouth disease antigen is 1:05~1.5.
The present invention also provides the preparation methods of the aftosa vaccine, and emulsion type adjuvant and foot-and-mouth disease antigen are preheated to 15
~30 DEG C, emulsion type adjuvant is mixed with foot-and-mouth disease antigen, it is hand or stir evenly, obtain aftosa vaccine.
The present invention is used for the emulsion type adjuvant of aftosa vaccine, replaces part mineral oil using vitamin E, selects hypotoxicity
Surfactant, the aftosa vaccine containing the adjuvant is under the premise of stability, immunoenhancement result are preferable, in the short period
It is inside easily fully absorbed by animal, avoids inoculation position inflammation, therefore significantly reduce the toxic side effect to animal.Emulsion type assistant
Agent and inactivation antigen can be stirred by hand, magnetic agitation or machine, and stable W/O/W type vaccine is made.Preparation process without
Precision instrument is needed, easy to operate, preparation cost is low.The present invention contains the aftosa vaccine of emulsion type adjuvant, and injection is convenient, preparation
Method is simple, efficient, safe.
Specific embodiment
Embodiment 1 prepares emulsion type adjuvant
Emulsogen EL360 is purchased from Clariant Chemical Co., Ltd., product number CNP1004847 in the present embodiment；Firmly
Lipidol polyoxyethylene (21) ether is purchased from Shanghai Mei Hao Fine Chemical Co., Ltd, product number PCN/4500713528.
Emulsion type adjuvant 1 is formulated:
Emulsion type adjuvant 2 is formulated:
Emulsion type adjuvant 3 is formulated:
Adjuvant 1 is compareed to be formulated:
Control adjuvant 2 formula (be 104398478 A of Publication No. CN, title " the emulsion type carrier of veterinary drug and its
Using " the oily phase 3 of embodiment 1 in application for a patent for invention):
Emulsion type adjuvant 1-3 and control adjuvant 1,2 are prepared, the specific method is as follows: weighing each component according to formula, mixed,
It stirs evenly, is used autoclaving 20 minutes under the conditions of 115 DEG C.Adjuvant is kept in dark place in room temperature.
The preparation of 2 aftosa vaccine of embodiment (W/O/W type)
Schweineseuche inactivation of viruses liquid (O-shaped, Mya98 plants) is provided by Jinyu Baoling Biology Drugs Co., Ltd, before inactivation
Viral level is 10 in every 0.2 milliliter of virus liquid7.17LD50。
Emulsion type adjuvant 1-3, control adjuvant 1 are mixed with Schweineseuche inactivation of viruses liquid according to mass ratio 1:1 respectively, led to
It crosses hand 5-10 minutes or is stirred 30 minutes under the conditions of 250rpm, be uniformly mixed each component, obtain aftosa vaccine, mouth hoof
The number of epidemic disease vaccine and the corresponding relationship of adjuvant are shown in Table 1.Adjuvant, virus liquid are preferably preheated to 15~30 DEG C before mixing.According to
Embodiment in 104398478 A of Publication No. CN, title " the emulsion type carrier of veterinary drug and its application " application for a patent for invention
Aftosa vaccine is made with Schweineseuche inactivation of viruses liquid (O-shaped, Mya98 plants) in control adjuvant 2 by 3 methods, and number is vaccine E.
| Adjuvant number | Vaccine number |
| Emulsion type adjuvant 1 | Aftosa vaccine A |
| Emulsion type adjuvant 2 | Aftosa vaccine B |
| Emulsion type adjuvant 3 | Aftosa vaccine C |
| Compare adjuvant 1 | Aftosa vaccine D |
| Compare adjuvant 2 | Aftosa vaccine E |
Aftosa vaccine A-E is W/O/W type, their physical behavior is consistent, and emulsion is in pale pink, wall when shake
On slightly light blue dosage form.Aftosa vaccine A-E is detected with the following method: being taken a 250mL beaker, is held 100mL cold water, take
One cleaning suction pipe draws a little vaccine drop in cold water surface, and the drop of each vaccine is in cloud diffusion.Viscosity: 1mL suction pipe is used
(exit inside diameter 1.2mm) draws 25 DEG C or so of vaccine 1.0mL, its vertical natural is enabled to flow out, when needed for record outflow 0.4mL
Between, as a result: the delivery time of each vaccine is within 8 seconds.Partial size: it accurately takes 10 μ L of vaccine in test cup with liquid-transfering gun, adds
Enter 290 μ L PBS buffer solution to mix well, it is ensured that test cup is put into Malvern nano particle size instrument by emulsified particles fine dispersion
Measurement, measuring temperature are set as 25 DEG C, and as a result the average grain diameter of each vaccine is within the scope of 130-190nm.Centrifugal stability: epidemic disease is taken
Seedling 10mL is added in centrifuge tube, is centrifuged 15min in 3000rpm/min, holds the tube bottom of each vaccine without precipitation water phase.37 DEG C steady
It is qualitative: vaccine to be placed in 37 DEG C of incubators, timing is observed daily, and each vaccine is not demulsified after placing 14 days.Aftosa vaccine A-E
It is placed 12 months in 4 DEG C of refrigerators, it is stable.
The safety verification of embodiment 3 aftosa vaccine A, B, C
Examine safety of the aftosa vaccine A-E to mouse and pig in embodiment 2.
(1) mouse safety test
16-22g cleaning grade mouse 60 is taken, is randomly divided into 6 groups, wherein one group is not inoculated with as control, other five component
Not Mian Yi aftosa vaccine A, B, C, D or E, 1/2 part is subcutaneously injected in every mouse neck, and (0.5ml, 1/2 part here are
Relative to pig) aftosa vaccine.1 week after vaccine inoculation, 2 weeks, 3 weeks, each group analyses mouse 3 at random, observes injection site
Absorbing state the results are shown in Table 2.It can be seen from Table 2 that: Mice Inoculated injection site is analysed, 2 weeks after the injection of vaccine A, B, C group
3/3 fully absorbs；It only 1/3 fully absorbs within 2 weeks after the injection of D group, just 3/3 fully absorbs within 3 weeks after injection；E group injection after 2 weeks only
There is 1/3 to fully absorb, just 3/3 fully absorbs within 3 weeks after injection.Mouse safety test result explanation: adjuvant 1-3 system of the present invention is used
Standby aftosa vaccine is just fully absorbed by total Test animal for two weeks after injection, is avoided since vaccine is not complete for a long time
Hypersorption inflammation caused by inoculation position, thus compared with comparing adjuvant 1,2, side reaction is significantly reduced, it is highly-safe.
The safety verification result of 2 aftosa vaccine of table
(2) pig safety test
30-35 age in days sodium selenite each 30 of foot-and-mouth disease antibody feminine gender are taken, 6 groups are randomly divided into, wherein one group is not inoculated with
Group is compared, in addition five groups of difference inoculation mouth fever aphthous vaccines A, B, C, D or E, 4 part (4ml) aftosa epidemic diseases of every intramuscular injection
Seedling.
Observed 14 days after inoculation, all test pig observation index include body temperature, spirit, appetite etc. part, general reaction with
And injection site absorbing state is analysed, it the results are shown in Table 3.It can be seen from Table 3 that: all test pig spirit, body temperature, appetite etc. are equal
No abnormality seen.Vaccine inoculation piglet has no abnormal response caused by vaccine inoculation.It cuts open high dose (4ml) Pigs Inoculated injection site
Solution, all pigs fully absorb after aftosa vaccine A, B, C are inoculated with 14 days, only 2/5 pig after aftosa vaccine D is inoculated with 14 days
It fully absorbs, only 1/5 pig fully absorbs after aftosa vaccine E is inoculated with 14 days.Pig safety test result explanation, present invention assistant
The aftosa vaccine of agent 1-3 preparation, can be fully absorbed by total Test animal after injection, avoid since vaccine is long for two weeks
Time does not fully absorb the inflammation caused by inoculation position, therefore, compared with comparing adjuvant 1,2, significantly reduces side reaction, peace
Quan Xinggao.
3 aftosa vaccine safety verification result of table
Above-mentioned safety testing result explanation, the present invention replace part mineral oil using vitamin E, select hypotoxicity surface
Activating agent avoids so that easily being fully absorbed by animal in the aftosa vaccine short time since vaccine does not fully absorb for a long time
The inflammation caused by inoculation position, to be substantially reduced the toxic side effect to animal.
The Study On Immunogenicity of embodiment 4 aftosa vaccine A, B, C
1, pig Study On Immunogenicity
Detect the immunogenicity of aftosa vaccine A, B, C.Healthy 2-3 month pigs 20 are grouped test, are divided into 4
Group, every group 5.It is not inoculated with as blank control for one group wherein, in addition three groups of difference inoculation mouth fever aphthous vaccine A, B, C, every connects
Kind 1ml.Blood sampling in 28 days separates serum after immune, (raw purchased from animal before the section of Wuhan with Schweineseuche ELISA antibody assay kit
Tetramune Co., Ltd) detection ELISA value for antibody, value for antibody >=6log2 is the positive.
It the results are shown in Table 4, vaccine single immunization pig ELISA antibody whole turn sun after 4 weeks.It should be the result shows that multiple with the present invention
The aftosa vaccine of newborn adjuvant preparation has preferable immunogenicity, and it is good vaccine adjuvant that antibody level is high after being immunized.
The ELISA antibody (log2) that the different aftosa vaccine immune swines of table 4 generate
| Grouping | Aftosa vaccine A | Aftosa vaccine B | Aftosa vaccine C | Blank control |
| 1 | 6 | 7 | 7 | 2 |
| 2 | 7 | 7 | 7 | 3 |
| 3 | 7 | 7 | 7 | 2 |
| 4 | 7 | 8 | 7 | 2 |
| 5 | 7 | 7 | 7 | 3 |
| Average value | 6.8 | 7.2 | 7.0 | 2.4 |
2, Mouse immunogenicity comparative test
Test vaccine: the aftosa vaccine A prepared in 1. embodiments 2；2.206 Adjuvanted vaccines: ISA206 adjuvant (is purchased from
SEPPIC company) foot-and-mouth disease antigen in the same manner as in Example 2 mixes with mass ratio 1:1, is prepared after emulsification；3. white oil is helped
Vaccinating agent: white oil foot-and-mouth disease antigen in the same manner as in Example 2 is mixed with mass ratio 2:1, is obtained after emulsification.4. in embodiment 2
The aftosa vaccine E of preparation.
20g or so cleaning grade mouse 25 is taken, aftosa vaccine A group, 206 Adjuvanted vaccines groups, white-oil adjuvant are randomly divided into
Vaccine group, aftosa vaccine E group and blank control group, every group has 5 mouse, in addition to blank control group is not immune, other each groups
Vaccine corresponding with its group name is immunized, in addition to 0.3ml/ is immunized only in white-oil adjuvant vaccine group, other immune group necks are subcutaneously infused
Penetrate 0.2ml/ only.28 days after immune, (have purchased from animal biological product before the section of Wuhan with aftosa ELISA antibody assay kit
Limit responsible company) detection ELISA value for antibody.
Mouse immunogenicity trial the results are shown in Table 5, from 4 weeks ELISA antibody levels after mouse single immunization visible in the table,
Aftosa vaccine A group antibody titer is higher than 206 Adjuvanted vaccines groups and aftosa vaccine E group, shows emulsion adjuvant immunity of the present invention
Effect meets or exceeds ISA206 adjuvant and the existing emulsion type adjuvant containing a large amount of mineral oil；Aftosa vaccine A group potency is omited
Lower than white-oil adjuvant vaccine group, show that adjuvant immunity effect of the present invention close to white-oil adjuvant, meets W/O/W type adjuvanted immunogenic
Infer lower than W/O adjuvant.
28 days ELISA antibody titers (log2) after 5 mouse immune of table
Claims (6)
1. being used for the emulsion type adjuvant of aftosa vaccine, it is grouped as by the group of following mass parts:
50-65 parts of mineral oil,
10-35 parts of vitamin E,
3-5 parts of castor oil ethyl oxide,
2-8 parts of Tween 80,
2-6 parts of n-amyl alcohol,
1-4 parts of Brij-721,
1-5 parts of deionized water；
The castor oil ethyl oxide is Emulsogen EL360, and the Brij-721 is stearyl alcohol polyoxy second
Alkene (21) ether.
2. the preparation method described in claim 1 for the emulsion type adjuvant of aftosa vaccine, each component is mixed, stirring is equal
It is even, sterilizing.
3. the aftosa vaccine containing emulsion type adjuvant described in claim 1.
4. aftosa vaccine according to claim 3, it is characterised in that vaccine emulsion type adjuvant as described in claim 1
It is formed with foot-and-mouth disease antigen.
5. aftosa vaccine according to claim 4, it is characterised in that the quality of the emulsion type adjuvant and foot-and-mouth disease antigen
Than for 1:05~1.5.
6. the preparation method of aftosa vaccine described in claim 5, it is characterised in that emulsion type adjuvant and foot-and-mouth disease antigen is pre-
Heat is mixed to 15~30 DEG C, by emulsion type adjuvant with foot-and-mouth disease antigen, hand or stir evenly, and obtains aftosa vaccine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610963355.XA CN106511996B (en) | 2016-11-04 | 2016-11-04 | Emulsion type adjuvant and preparation method thereof for aftosa vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610963355.XA CN106511996B (en) | 2016-11-04 | 2016-11-04 | Emulsion type adjuvant and preparation method thereof for aftosa vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106511996A CN106511996A (en) | 2017-03-22 |
| CN106511996B true CN106511996B (en) | 2019-09-10 |
Family
ID=58326355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610963355.XA Active CN106511996B (en) | 2016-11-04 | 2016-11-04 | Emulsion type adjuvant and preparation method thereof for aftosa vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511996B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111789943B (en) * | 2019-04-08 | 2024-01-19 | 洛阳赛威生物科技有限公司 | Oil-in-water adjuvant composition and preparation method and application thereof |
| CN111358944B (en) * | 2020-02-29 | 2021-12-31 | 浙江大学 | Composite vegetable oil vaccine adjuvant and application thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679933A (en) * | 2005-01-07 | 2005-10-12 | 邢为藩 | Self-emulsifying vaccine adjuvant and preparation thereof |
| CN101522218A (en) * | 2006-10-12 | 2009-09-02 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine comprising an oil in water emulsion adjuvant |
| CN101703771A (en) * | 2009-11-13 | 2010-05-12 | 广东温氏食品集团有限公司 | Oil-in-water type compound vaccine adjuvant and method for preparing same |
| CN102274498A (en) * | 2011-07-11 | 2011-12-14 | 李映波 | Foot and mouth disease virus nano-emulsion adjuvant vaccine and preparation method thereof |
| CN102600470A (en) * | 2012-03-29 | 2012-07-25 | 江苏省农业科学院 | Compound adjuvant, vaccine containing the same, and its preparation method |
| CN102813922A (en) * | 2012-09-11 | 2012-12-12 | 山东省农业科学院畜牧兽医研究所 | Compound oil adjuvant as well as preparation method and application thereof |
| CN103071153A (en) * | 2013-01-21 | 2013-05-01 | 江苏省农业科学院 | Ready-to-use adjuvant of livestock vaccines, preparation and applications thereof |
| CN104147599A (en) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | Vaccine adjuvant as well as preparation method and application thereof |
| CN104998256A (en) * | 2015-07-14 | 2015-10-28 | 天津瑞普生物技术股份有限公司 | Preparation method of triple inactivated vaccine for pigs |
| CN105688207A (en) * | 2016-03-11 | 2016-06-22 | 中牧实业股份有限公司 | Compound adjuvant for animal vaccine and application of compound adjuvant |
| CN105727284A (en) * | 2016-03-22 | 2016-07-06 | 中国农业科学院兰州兽医研究所 | Dual-phase nano emulsion adjuvant used for vaccines of pig and cow foot-and-mouth disease as well as preparation method and application of dual-phase nano emulsion adjuvant |
-
2016
- 2016-11-04 CN CN201610963355.XA patent/CN106511996B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679933A (en) * | 2005-01-07 | 2005-10-12 | 邢为藩 | Self-emulsifying vaccine adjuvant and preparation thereof |
| CN101522218A (en) * | 2006-10-12 | 2009-09-02 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine comprising an oil in water emulsion adjuvant |
| CN101703771A (en) * | 2009-11-13 | 2010-05-12 | 广东温氏食品集团有限公司 | Oil-in-water type compound vaccine adjuvant and method for preparing same |
| CN102274498A (en) * | 2011-07-11 | 2011-12-14 | 李映波 | Foot and mouth disease virus nano-emulsion adjuvant vaccine and preparation method thereof |
| CN102600470A (en) * | 2012-03-29 | 2012-07-25 | 江苏省农业科学院 | Compound adjuvant, vaccine containing the same, and its preparation method |
| CN102813922A (en) * | 2012-09-11 | 2012-12-12 | 山东省农业科学院畜牧兽医研究所 | Compound oil adjuvant as well as preparation method and application thereof |
| CN103071153A (en) * | 2013-01-21 | 2013-05-01 | 江苏省农业科学院 | Ready-to-use adjuvant of livestock vaccines, preparation and applications thereof |
| CN104147599A (en) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | Vaccine adjuvant as well as preparation method and application thereof |
| CN104998256A (en) * | 2015-07-14 | 2015-10-28 | 天津瑞普生物技术股份有限公司 | Preparation method of triple inactivated vaccine for pigs |
| CN105688207A (en) * | 2016-03-11 | 2016-06-22 | 中牧实业股份有限公司 | Compound adjuvant for animal vaccine and application of compound adjuvant |
| CN105727284A (en) * | 2016-03-22 | 2016-07-06 | 中国农业科学院兰州兽医研究所 | Dual-phase nano emulsion adjuvant used for vaccines of pig and cow foot-and-mouth disease as well as preparation method and application of dual-phase nano emulsion adjuvant |
Non-Patent Citations (5)
| Title |
|---|
| 不同佐剂制备牛口蹄疫O型灭活疫苗的效力评价试验;辛俊宝等;《中国奶牛》;20131231;36-38 * |
| 免疫增强剂在养猪业上的研究与应用进展;刘瑞生;《养猪》;20160410(第2期);31-37 * |
| 免疫增强剂在动物医学上的研究进展及应用;张成裕;《福建畜牧兽医》;20041231;61-63 * |
| 免疫增强剂提升猪用灭活疫苗免疫效力的研究;唐波等;《中国兽药杂志》;20160620;第50卷(第6期);5-8 * |
| 口蹄疫双佐剂灭活疫苗的研究;黄炯;《中国畜牧兽医》;20091231;91-93 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106511996A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2712278C2 (en) | Avian vaccination system and method | |
| Galliher-Beckley et al. | Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines | |
| CN103495160A (en) | Preparation method of inactivated mycoplasma synoviae vaccine | |
| CN106511996B (en) | Emulsion type adjuvant and preparation method thereof for aftosa vaccine | |
| CN103083663A (en) | Immunity enhancing agent, inactivated vaccine, and preparation method thereof | |
| CN103816537A (en) | Nanometer adjuvant and preparation method for same | |
| Zhao et al. | O/W nanoemulsion as an adjuvant for an inactivated H3N2 influenza vaccine: based on particle properties and mode of carrying | |
| CN102580082B (en) | Inactived vaccine for poultry and preparation method thereof | |
| CN107596364A (en) | A kind of w/o/w adjunvant compositions, the vaccine combination prepared and preparation method thereof | |
| CN105797153A (en) | Veterinary vaccine immunologic adjuvant as well as preparation and application method thereof | |
| CN102743750B (en) | Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent | |
| Burakova et al. | Food-grade saponin extract as an emulsifier and immunostimulant in emulsion-based subunit vaccine for pigs | |
| CN104258389A (en) | Vaccine composition as well as preparation method and application thereof | |
| CN105854013B (en) | A kind of animal vaccine oil adjuvant and its animal vaccine | |
| CN102580079A (en) | Porcine parvovirus nanometer alumina gel adjuvant inactivated vaccine and preparation method thereof | |
| Augustyniak et al. | Vaccination failures in pigs—the impact of chosen factors on the immunisation efficacy | |
| CN105727284B (en) | A kind of biphase cream adjuvant and its preparation method and application for pigs and cattle aftosa vaccine | |
| CN105148266B (en) | A kind of w/o type vaccine oil adjuvant preparation and preparation method thereof | |
| CN107684621A (en) | Application of the corynebacterium diphtheroides as immunologic adjuvant in fowl oil emulsion inactivated vaccine | |
| CN104771754B (en) | A kind of porcine circovirus 2 type inactivated vaccine aqueous adjuvants and application | |
| Ebrahimi et al. | Safety and efficacy of reduced doses of Brucella melitensis strain Rev. 1 vaccine in pregnant Iranian fat-tailed ewes. | |
| CN103789272B (en) | H9 subtype avian influenza virus separation strain and the vaccine combination prepared by it | |
| CN105168133B (en) | A kind of oil emu preparation method | |
| CN110179975B (en) | Vegetable oil vaccine adjuvant and preparation method and application thereof | |
| CN113713093A (en) | Novel tretinoin nanoemulsion adjuvant capable of efficiently enhancing humoral immune response and mucosal immune response and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210902 Address after: No. 1050, science and innovation center, Nanjing National Agricultural Innovation Park, No. 8 Zhixing Road, Pukou District, Nanjing, Jiangsu 210000 Patentee after: Nanjing Guochuang Biotechnology Research Institute Co.,Ltd. Address before: Zhong Ling Jie Nanjing Xuanwu District of Jiangsu Province, No. 50 210014 Patentee before: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES |
|
| TR01 | Transfer of patent right |